Cephalotaxine

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

In controlled trials, serum aminotransferase elevations occurred in 2% to 6% patients treated with omacetaxine, but most elevations were mild and transient with only rare patients requiring dose modification or discontinuation for liver test abnormalities. Clinically apparent liver injury with jaundice was not reported in the preregistration trials of omacetaxine and is not mentioned in the product label. Since the approval and more wide scale use of omacetaxine, there have been no publications or descriptions of the hepatotoxicity with jaundice associated with its use. Thus, clinically apparent liver injury due to omacetaxine must be rare, if it occurs at all.

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins.